{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Nonsmall+Cell+Lung+Cancer&page=66",
    "query": {
      "condition": "Advanced Nonsmall Cell Lung Cancer",
      "page": 66
    },
    "page_size": 10
  },
  "pagination": {
    "page": 66,
    "page_size": 10,
    "total_count": 1771,
    "total_pages": 178,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Nonsmall+Cell+Lung+Cancer&page=67&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Nonsmall+Cell+Lung+Cancer&page=65&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-21T11:53:29.249Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01233687",
      "title": "AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "interventions": [
        {
          "name": "AMG 102 and erlotinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ahmad Tarhini",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 49,
      "start_date": "2011-08",
      "completion_date": "2014-11",
      "has_results": true,
      "last_update_posted_date": "2017-06-22",
      "last_synced_at": "2026-11-21T11:53:29.249Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01233687"
    },
    {
      "nct_id": "NCT03793179",
      "title": "Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Lung Non-Squamous Non-Small Cell Carcinoma",
        "Stage IIIB Lung Cancer AJCC v8",
        "Stage IIIC Lung Cancer AJCC v8",
        "Stage IV Lung Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 600,
      "start_date": "2019-04-05",
      "completion_date": "2027-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-11-12",
      "last_synced_at": "2026-11-21T11:53:29.249Z",
      "location_count": 1081,
      "location_summary": "Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 694 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03793179"
    },
    {
      "nct_id": "NCT02637531",
      "title": "A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors (Part A/B/C/D)",
        "Non-small Cell Lung Cancer (Part E)",
        "Melanoma (Part E)",
        "Squamous Cell Cancer of the Head and Neck (Part E)",
        "Triple Negative Breast Cancer (Part F)",
        "Adrenocortical Carcinoma (Part G)",
        "Mesothelioma (Part G)",
        "High-circulating Myeloid-derived Suppressor Cells (Part H)"
      ],
      "interventions": [
        {
          "name": "IPI-549 (eganelisib)",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Infinity Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 219,
      "start_date": "2015-12",
      "completion_date": "2022-12",
      "has_results": false,
      "last_update_posted_date": "2022-04-04",
      "last_synced_at": "2026-11-21T11:53:29.249Z",
      "location_count": 11,
      "location_summary": "San Diego, California • Santa Monica, California • Port Saint Lucie, Florida + 6 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Port Saint Lucie",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02637531"
    },
    {
      "nct_id": "NCT00948675",
      "title": "Study of Participants With Advanced Non-Small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Advanced Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 361,
      "start_date": "2009-09-01",
      "completion_date": "2020-11-06",
      "has_results": true,
      "last_update_posted_date": "2021-10-29",
      "last_synced_at": "2026-11-21T11:53:29.249Z",
      "location_count": 45,
      "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Mission Hills, California + 42 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Mission Hills",
          "state": "California"
        },
        {
          "city": "Aventura",
          "state": "Florida"
        },
        {
          "city": "Daytona Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00948675"
    },
    {
      "nct_id": "NCT01737502",
      "title": "Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Extensive Stage Small Cell Lung Carcinoma",
        "Lung Adenocarcinoma",
        "Recurrent Non-Small Cell Lung Carcinoma",
        "Recurrent Small Cell Lung Carcinoma",
        "Squamous Cell Lung Carcinoma",
        "Stage IIIA Non-Small Cell Lung Cancer",
        "Stage IIIB Non-Small Cell Lung Cancer",
        "Stage IV Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Auranofin",
          "type": "DRUG"
        },
        {
          "name": "Sirolimus",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 29,
      "start_date": "2014-05-14",
      "completion_date": "2023-04-24",
      "has_results": true,
      "last_update_posted_date": "2025-09-05",
      "last_synced_at": "2026-11-21T11:53:29.249Z",
      "location_count": 2,
      "location_summary": "Scottsdale, Arizona • Jacksonville, Florida",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01737502"
    },
    {
      "nct_id": "NCT04703153",
      "title": "LIQUIK: LIQUId Biopsy for Detection of Actionable Genomic BiomarKers in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Non Small Cell Lung Cancer"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Lucence Health Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 151,
      "start_date": "2021-04-05",
      "completion_date": "2024-12-31",
      "has_results": false,
      "last_update_posted_date": "2023-03-09",
      "last_synced_at": "2026-11-21T11:53:29.249Z",
      "location_count": 5,
      "location_summary": "Los Angeles, California • Miami, Florida • Honolulu, Hawaii + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Honolulu",
          "state": "Hawaii"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Belleville",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04703153"
    },
    {
      "nct_id": "NCT00100854",
      "title": "Erlotinib With or Without Fulvestrant in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lung Cancer"
      ],
      "interventions": [
        {
          "name": "erlotinib hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "fulvestrant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Translational Oncology Research International",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 108,
      "start_date": "2004-10-28",
      "completion_date": "2018-09-05",
      "has_results": false,
      "last_update_posted_date": "2019-03-05",
      "last_synced_at": "2026-11-21T11:53:29.249Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00100854"
    },
    {
      "nct_id": "NCT02014337",
      "title": "Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer",
        "Ovarian Epithelial Cancer Recurrent",
        "Sarcoma",
        "Non-small Cell Lung Cancer",
        "Carcinoma, Transitional Cell",
        "Prostate Cancer",
        "Prostatic Neoplasms"
      ],
      "interventions": [
        {
          "name": "Mifepristone and Eribulin in combination",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Corcept Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 37,
      "start_date": "2014-01",
      "completion_date": "2017-12",
      "has_results": false,
      "last_update_posted_date": "2018-01-17",
      "last_synced_at": "2026-11-21T11:53:29.249Z",
      "location_count": 11,
      "location_summary": "Tucson, Arizona • Tampa, Florida • Atlanta, Georgia + 8 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Royal Oaks",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02014337"
    },
    {
      "nct_id": "NCT00977470",
      "title": "Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Erlotinib",
          "type": "DRUG"
        },
        {
          "name": "Hydroxychloroquine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 76,
      "start_date": "2009-10",
      "completion_date": "2027-12",
      "has_results": true,
      "last_update_posted_date": "2025-10-15",
      "last_synced_at": "2026-11-21T11:53:29.249Z",
      "location_count": 4,
      "location_summary": "Stanford, California • New Haven, Connecticut • Baltimore, Maryland + 1 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00977470"
    },
    {
      "nct_id": "NCT00369551",
      "title": "Bevacizumab, Paclitaxel, Carboplatin, and Radiation Therapy to the Chest in Treating Patients With Locally Advanced Non-Small Cell Lung Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Adenocarcinoma of the Lung",
        "Bronchoalveolar Cell Lung Cancer",
        "Large Cell Lung Cancer",
        "Stage II Non-small Cell Lung Cancer",
        "Stage IIIA Non-small Cell Lung Cancer",
        "Stage IIIB Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "3-dimensional conformal radiation therapy",
          "type": "RADIATION"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "carboplatin",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2006-06",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2014-03-06",
      "last_synced_at": "2026-11-21T11:53:29.249Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00369551"
    }
  ]
}